Uterine endometrial fluid for prediction of success in fertility treatment
Non-invasive uterine microenvironment analysis using endometrial secretion markers enhances fertility treatment success by predicting and correcting unsuitable conditions, addressing the limitations of current grading methods and hormonal assessments.
Patent Information
- Application Number
- JP2024137634
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-04-30
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for predicting implantation success in fertility treatments, such as IVF, are inaccurate due to reliance on morphological embryo grading and hormonal assessments that do not account for chromosomal integrity and embryonic metabolism, leading to low success rates and increased risks of multiple pregnancies.
Non-invasive sampling of the uterine microenvironment to analyze endometrial secretions for specific markers like proteins, metabolites, and miRNAs, which can predict an unsuitable endometrial environment by comparing their presence to profiles associated with successful pregnancy outcomes.
Improves pregnancy success rates by identifying and addressing unsuitable endometrial conditions before embryo transfer, reducing the risk of implantation failure and multiple pregnancies.
Smart Images

Figure 2024160361000005 
Figure 2024160361000006 
Figure 2024160361000007
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 USC 119(e) to U.S. Provisional Patent Application No. 62 / 796,695, entitled "Uterine Endometrial Fluid for Prediction of Success in Fertility Treatment," filed January 25, 2019, and U.S. Provisional Patent Application No. 62 / 841,008, entitled "Uterine Endometrial Fluid for Prediction of Success in Fertility Treatment," filed April 30, 2019, each of which is incorporated herein by reference. To the extent appropriate, priority is claimed to each of the above-disclosed applications.
[0002] The present invention relates to the field of infertility treatment. More specifically, for example, when a fertilized egg is implanted in a patient's uterus, evaluation of the uterine microenvironment is used to increase the success rate of pregnancy. In addition, manipulation of the uterine microenvironment improves the chances of pregnancy in both natural and artificial cycles. [Background technology]
[0003] Despite incremental improvements in IVF pregnancy rates, the majority of transferred human embryos result in implantation failure. For example, the Society for Assisted Reproductive Technology (reported to approximately 80% of fertility clinics in the United States) reported that in 2015, IVF success rates (% of patients who have had a live birth using the patient's own eggs) were 56.7% for women under 35 years old, 44.4% for women aged 35-37 years, 30.7% for women aged 38-40 years, 15.1% for women aged 41-42 years, and 4.5% for women over 42 years old. Obviously, when donor eggs are not used, implantation success rates decrease with increasing maternal age. Various factors are associated with implantation failure, including embryonic chromosomal aneuploidies associated with advancing maternal age, and maternal factors such as impaired endometrial response to hormonal regulation.
[0004] To overcome low implantation success rates, various approaches are typically taken. In the past, and some clinics still practice, transferring multiple embryos during a single IVF procedure to improve the chances of implantation. The process of selecting embryos for transfer often involves grading methods developed by individual laboratories to determine the quality of oocytes and embryos. An arbitrary embryo score involving the number and quality of embryos may reveal the probability of successful pregnancy after transfer. For example, embryologists may grade embryos using morphological qualities including cell number, clarity of cytoplasm, evenness of growth, and degree of fragmentation. Often, several embryos selected for these general qualities are implanted to improve the chances of pregnancy. However, embryo selection based on morphological quality is not accurate. For example, morphological evaluation fails to evaluate two factors related to embryo viability: chromosomal integrity and embryo metabolism. In clinics that perform morphological screening of embryos, the number of embryos to be transferred depends on the number of viable embryos available, the age of the woman, and other health and diagnostic factors.
[0005] However, the transfer of multiple embryos often results in multiple pregnancies, a major complication of IVF. In general, multiple pregnancies, especially those with triplets or more, are risky for the mother and fetus. For example, multiple births are associated with increased risks of pregnancy loss, neonatal morbidity, delivery complications, and preterm birth with potential long-term damage. To reduce the risk of multiple pregnancies with triplets or more (e.g., triplets or more), some countries have implemented strict limitations on the number of embryos transferred, and the American Society for Reproductive Medicine has its own guidelines for the number of embryos to be transferred. However, these limitations are not widely adhered to or accepted.
[0006] In parallel with embryo preparation, the female patient's hormonal manipulation prepares the uterine environment to receive the embryo(s) so that both the embryo and the patient are simultaneously ready for embryo transfer. Hormonal manipulation involves administration of estrogen and progesterone at levels required to mimic or exceed circulating blood levels of estrogen and progesterone in normal women near the end of their typical monthly cycle.
[0007] Commercial endometrial receptivity tests are offered to infertility patients to test 30-90 days prior to embryo transfer, but the results do not necessarily indicate the uterine environment at the time of embryo transfer. Endometrial thickness is measured by ultrasound immediately prior to frozen embryo transfer, and blood reproductive hormones are monitored, but there is currently no way to test whether a woman's uterus will be receptive in the current cycle. To improve the success rate of infertility treatments and to assist women with endometrial infertility, a method is needed to identify a patient's receptive endometrium. Summary of the Invention [Means for solving the problem]
[0008] Provided herein are methods, systems, and kits for obtaining, using, and / or analyzing data associated with improved success rates of fertility treatments. In some embodiments, the data is obtained by non-invasively sampling the patient's uterine microenvironment for a current treatment cycle, i.e., a cycle that coincides with a planned embryo transfer or intrauterine insemination, rather than a cycle several months prior to the planned procedure.
[0009] Thus, a method for predicting poor pregnancy outcome of infertility treatment is provided herein.In some embodiments, the method includes: (a) contacting the endometrial secretion of a patient with a kit comprising a solid substrate functionalized to identify at least two markers associated with unsuitable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs; and (b) determining the secretome profile of the endometrial secretion to confirm the increase or decrease in the presence of the markers associated with unsuitable endometrial environment.The increase or decrease in the presence of one or more markers associated with unsuitable endometrial environment compared to the secretome profile of the endometrial secretion of successful pregnancy predicts poor pregnancy outcome.
[0010] Provided herein is a kit comprising a solid substrate functionalized to identify one or more markers, or at least two markers, associated with an unfavorable endometrial environment, selected from the group consisting of proteins, metabolites, and miRNAs. The kit can include an immunosorbent assay, instructions on how to perform the assay, a model for classifying data obtained from the assay, and / or a secretome profile of endometrial secretions associated with successful pregnancy outcomes.
[0011] Also provided herein is a system for improving the pregnancy success rate of infertility treatment. In some embodiments, the system includes predicting a poor pregnancy outcome of a patient undergoing infertility treatment prior to frozen embryo transfer or intrauterine insemination. The predicting step includes determining a secretome profile of the patient's endometrial secretions to identify an increased or decreased presence of markers associated with an unfavorable endometrial environment. An increased or decreased presence of one or more markers associated with an unfavorable endometrial environment compared to a secretome profile of the endometrial secretions associated with a successful pregnancy outcome predicts a poor pregnancy outcome of the patient.
[0012] In some embodiments, the step of determining the secretome profile of the endometrial secretion comprises contacting the patient's endometrial secretion with a kit comprising a solid substrate functionalized to identify at least two markers associated with an unfavorable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs, and determining the secretome profile of the endometrial secretion to confirm an increase or decrease in the presence of the markers associated with an unfavorable endometrial environment.
[0013] Provided herein is an in vitro method for screening infertility patients before frozen embryo transfer or intrauterine insemination.In some embodiments, the method includes: (a) contacting the endometrial secretion of the patient with a kit comprising a solid substrate functionalized to identify at least two markers associated with an unsuitable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs; and (b) determining the secretome profile of the endometrial secretion to confirm the increase or decrease in the presence of the markers associated with an unsuitable endometrial environment.The increase or decrease in the presence of one or more markers associated with an unsuitable endometrial environment compared to the secretome profile of the endometrial secretion of successful pregnancy predicts poor pregnancy outcome.
[0014] In some embodiments, a method for predicting implantation failure of a candidate embryo is provided. The method includes: (a) contacting a patient's endometrial secretion with a kit comprising a solid substrate functionalized to identify at least two markers associated with an unsuitable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs; and (b) determining an endometrial secretion secretome profile to identify an increase or decrease in the presence of the markers associated with an unsuitable endometrial environment. An increase or decrease in the presence of one or more markers associated with an unsuitable endometrial environment compared to the secretome profile of endometrial secretion of a successful pregnancy outcome predicts implantation failure of the embryo.
[0015] In some aspects, the marker is a protein. In some embodiments, the protein is selected from the group consisting of IL-6, IL-8, VEGF, mucin 1, mucin 16, mucin 5B, mucin 5AC, IgGFc binding protein, carbonic anhydrase 1, cystatin C, ITIH4, LTF, SERPING1, GC, CFH, FFT1, THSD4, ANPEP, COL6A1, PROM1, and PLG, and increased expression of the protein is associated with unsuitable endometrial environment. In some embodiments, the protein is selected from the group consisting of SOD1, PRDX6, PLA2G4D, and TET1, and decreased expression of the protein is associated with unsuitable endometrial environment.
[0016] In some embodiments, the marker is arginine, and decreased levels of arginine are associated with an unfavorable endometrial environment.
[0017] In some aspects, the marker is a microRNA. In some embodiments, the microRNA is selected from the group consisting of hsa-miR-891a, hsa-miR-522, hsa-miR-198, and hsa-miR-365, and its decreased presence is associated with an unsuitable endometrial environment. In some embodiments, the microRNA is selected from the group consisting of hsa-miR-135a, hsa-miR-17, hsa-miR-10b, hsa-miR-126, hsa-miR-155, hsa-miR-19a, hsa-miR-150, hsa-miR-200c, hsa-miR-224, hsa-miR-140, hsa-miR-222, hsa-miR-31, hsa-miR-454, and hsa-miR-106c, and its increased presence is associated with an unsuitable endometrial environment.
[0018] In some aspects, the marker is a metabolite. In some embodiments, the metabolite is selected from the group consisting of xanthine, docosahexaenoic acid, fumarate, cysteine, putrescine, proline, leucine / isoleucine, hypoxanthine, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline, and a decrease in the presence of the metabolite is associated with an unsuitable endometrial environment. In some embodiments, the metabolite is selected from the group consisting of urate, citrate, orthophosphate, and heptanoic acid, and an increase in the presence of the metabolite is associated with an unsuitable endometrial environment.
[0019] In yet other embodiments, the patient's uterine microenvironment is observed and poor implantation outcome is evaluated 24 hours prior to embryo transfer. In aspirates from uterine microenvironments predicted to experience implantation failure, the interplay of several biological processes may be evident, in particular, a decrease in 13 transcripts, an increase in 7 maternal miRNAs, a decrease in 12 amino acids, and changes in abundance of 16 proteins. In some embodiments, a decrease in the expression of PLA2G4D, which regulates the eicosanoid pathway and thereby affects downstream synthesis of prostaglandins such as PGE2, may predict implantation failure. In some embodiments, a decrease in the expression of TET1, an epigenetic regulator required for DNA methylation, may predict implantation failure. In some embodiments, an increase in the level of miR-17, a known negative regulator of VEGFA required for successful implantation, may predict implantation failure. In some embodiments, a decrease in the amount of arginine, which is essential for blastocyst activation and trophectoderm motility, may predict implantation failure. Finally, increased abundance of SERPING1, a protein associated with inflammation and which regulates complement activation, may predict graft failure.
[0020] In one embodiment, a system is provided for increasing the pregnancy success rate of infertility patients. The system includes an electronic system configured to collect endometrial secretome data as a secretome profile by quantifying markers that are related to uterotoxicity. A model is provided for use in recommending the practice of embryo implantation or intrauterine insemination based on the secretome profile. The secretome data may be obtained, for example, by using mass spectrometry, qPCR, or ELISA measurement.
[0021] According to one embodiment of the system, a uterine secretome profile may be provided by identifying markers, e.g., microRNAs, metabolites, and proteins, in endometrial secretions that may be associated with altered likelihood of implantation success.
[0022] In one embodiment, a method of infertility treatment entails determining the secretome profile of the endometrium of an infertile patient, where the profile is created by measuring markers that are implicated in uterotoxicity. This provides data that may be submitted to a model that correlates one or more of these markers with changes in the likelihood of successful or unsuccessful embryo implantation. A recommendation for embryo implantation or intrauterine insemination may then be provided based on the modeled outcome. The embryo may be transferred conditionally based on the recommendation.
[0023] In one embodiment, there is an improved ELISA kit having multiple microwells for quantification of protein content in a sample, the microwells being constructed and arranged to quantify multiple proteins implicated in uterotoxicity. [Brief description of the drawings]
[0024] [Figure 1] FIG. 1 shows a PCA plot separating good and bad uterine samples with respect to their metabolite profiles. [Diagram 2]FIG. 2 identifies the differentially expressed metabolites. [Diagram 3] FIG. 3 provides box plots of each individual differentially expressed metabolite. [Figure 4] FIG. 4 provides box plots of each individual differentially expressed metabolite. [Diagram 5] FIG. 5 provides box plots of each individual differentially expressed metabolite. [Figure 6] FIG. 6 shows three cytokines (out of 30 analyzed) that were differentially expressed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] The following definitions are provided to facilitate understanding of certain terms used herein and are not intended to limit the scope of the disclosure.
[0026] The phrase "adverse pregnancy outcome" refers to the failure to implant an embryo in a woman's uterus or the failure to implant an embryo sufficiently to sustain embryonic life. This phrase may be used interchangeably with the phrase "implantation failure."
[0027] "Implantation failure" occurs when an otherwise desirable embryo fails to implant, and may be designated as repeated implantation failure when an otherwise desirable embryo fails to implant after several IVF treatment attempts.
[0028] The phrase "unsuitable endometrial environment" refers to the environment in the uterus that impairs embryo implantation.Specifically, the endometrial microenvironment where embryo implants may lack the appropriate support system for the implanting embryo, which ultimately leads to embryo implantation failure, resulting in poor pregnancy outcome.The unsuitable endometrial environment of the uterus may be associated with inflammation, for example, as a result of autoimmunity, or external inflammatory input, or may be associated with oxidative stress, or the body's inability to deal with oxidative stress.
[0029] The window of opportunity for implantation, which occurs naturally 6-10 days after ovulation, is the period of endometrial implantation competence. It is short and is the result of a programmed sequence of estrogen and progesterone on the endometrium. This is the critical time point where the embryo and endometrium meet each other and exchange their molecular dialogue for the first time. Within the endometrial structure, certain characteristic changes in adhesion must occur to allow for the attachment of the blastocyst, as well as the tight control of signaling pathways in the surrounding microenvironment. Successful molecular exchange between the embryo and the receptive endometrium must occur during the early stages of implantation. Implantation is characterized by structural and functional changes in the endometrial layer, and the secretion of nutrients, including numerous vitamin- and steroid-dependent proteins. Without this molecular exchange, the attachment of the blastocyst to the receptive uterus will fail.
[0030] Endometrial aspiration at the time of embryo transfer using a transfer catheter is an effective and minimally invasive means to sample the endometrial microenvironment in localized areas of the uterus. Endometrial aspirates taken 24 hours before embryo transfer contained specific prostaglandin levels that correlated with implantation success, and aspirate collection itself did not adversely affect pregnancy outcome (Vilella et al., 2013). Other commercially available techniques that provide insight into implantation opportunities rely on tissue from endometrial biopsies. However, these samples are obtained from previous cycles that may not represent the molecular status of the current cycle.
[0031] Provided herein are methods, kits, and systems that allow a rare glimpse into the microenvironment that the transferred embryo will encounter. This sampling technique allows for the identification of the etiology of patient pathology that may require additional medical intervention to achieve successful blastocyst implantation.
[0032] One of the more difficult patient populations to treat with ART is those who present with recurrent implantation failure, defined as when a woman has had three or more unsuccessful embryo transfer attempts with euploid embryos. There are a number of known factors that may contribute to implantation failure, including embryonic factors, including genetic abnormalities, in addition to maternal factors such as immune factors and endometrial dysfunction.
[0033] However, in the patient population with euploid embryos that have already been screened for known maternal factors and appropriately treated, there is still a subset with no clear cause of endometrial dysfunction.For these patients, the molecular factors that affect their endometrial microenvironment predict the success or failure of embryo implantation in a given cycle.Endometrial aspiration, when combined with OMICS technology, provides insight into the receptive conditions during the implantation window and allows the identification of factors potentially involved in infertility.
[0034] Interactions between the immune and endocrine systems appear to be necessary to develop an ideal environment for blastocyst implantation. A receptive endometrium allows for blastocyst penetration and rapid placental growth while supporting the transformation of uterine cells into decidual cells. This can be facilitated by immune cells already present in the uterus, cytokines secreted by those immune cells, and hormonal changes.
[0035] The most intensively studied aspects of the uterine microenvironment are uterine immune cells: maternal CD4+CD25+Foxp3+ regulatory T cells (Tregs), uterine natural killer cells (uNK cells), uterine dendritic cells (uDCs), uterine mast cells (uMCs), and uterine macrophages. However, little is known about the remaining parts of the uterine microenvironment that contribute to successful blastocyst implantation.
[0036] Provided herein are methods, systems, and kits for improving the success rate of pregnancy in infertility treatments, including, for example, embryo transfer or intrauterine insemination, or ovulation regulation or ovulation induction.Also provided herein are methods for treating female infertility, including: (a) determining miR-17 levels in the patient's endometrial secretions; (b) treating the patient with increased miR-17 levels in the endometrial secretions compared to the miR-17 profile indicating successful pregnancy outcomes with recombinant human VEGF-A; and (c) performing frozen embryo transfer or intrauterine insemination.In some embodiments, (a) is performed at least 24 hours before (c).Additional methods of treatment are contemplated, where if uterine markers are determined and decreased, proteins, amino acids, etc. can be administered to the patient in sufficient amounts to increase levels to provide a suitable endometrial environment for implantation.
[0037] In some embodiments, a method for predicting poor pregnancy outcome of infertility treatment is provided. Application of the method allows medical personnel to identify unacceptable uterus of infertile patients before performing frozen embryo transfer or intrauterine insemination. In some aspects, the method includes (a) contacting endometrial secretions of the patient with a kit including a solid substrate functionalized to identify at least two markers associated with an unsuitable endometrial environment, and (b) determining an endometrial secretion secretome profile to identify an increased or decreased presence of the markers associated with an unsuitable endometrial environment. The secretome profile of the endometrial secretions of the patient can be indicative of a toxic uterine environment when compared to the secretome profile of endometrial secretions of successful pregnancy outcomes. The secretome profile of the endometrial secretions of the patient can be indicative of implantation success or poor pregnancy outcome when compared to the secretome profile of endometrial secretions of successful pregnancy outcomes.
[0038] Inflammatory markers associated with an unfavorable endometrial environment include pro- and anti-inflammatory mediators, complement regulators, and / or proteins involved in chemotaxis. In some embodiments, endometrial secretions may contain increased levels of any one or more of ITIH4, LTF, SERPING1, GC, CHF, and / or CP.
[0039] Markers of oxidative stress associated with unfavorable endometrial environment include pro-oxidant / antioxidant effects, loss of antioxidants, and loss of the body's ability to deal with reactive oxygen species.In some embodiments, endometrial secretions may contain increased levels of any one or more of GGT1, LTF, or CFH.In some embodiments, endometrial secretions may contain decreased levels of SOD1 and / or PRDX6.
[0040] Markers involved in implantation associated with unsuitable endometrial environment include TFFB sequestration, trophoblast cell invasion, ECM remodeling, and uterine receptivity.In some embodiments, endometrial secretion may contain increased levels of any one or more of THSD4, ANPEP, COL6A1, PROM1, ITIH4, and PLG.In some embodiments, endometrial secretion may contain decreased levels of SOD1 and / or PRDX6.
[0041] In some embodiments, the endometrial secretion of the patient is obtained before thawing the embryo for implantation.For example, the endometrial secretion can be obtained within 48 hours of planned implantation, or within 36 hours of planned implantation, or within 24 hours of planned implantation, or within 18 hours of planned implantation, or within 12 hours of planned implantation.Typically, the embryo is thawed 1 hour before embryo implantation, and the secretome profile data can be obtained any time before thawing.The endometrial secretion sample is obtained non-invasively, i.e., no biopsy is required.In some embodiments, the sample is obtained by catheter.
[0042] By checking the health of the patient's uterine microenvironment before thawing the embryo, a decision can be made to postpone the embryo transfer procedure to a later cycle. This allows the embryo to be preserved from the thawing cycle and the viable embryo to be preserved for later transfer, which benefits the methods and systems provided herein. Another benefit of this process is that the patient's uterine microenvironment is evaluated for the current cycle, not the cycle several months before the planned transfer. This is important because the endometrial condition of an infertile patient may change from cycle to cycle.
[0043] Various markers associated with poor pregnancy outcome are provided herein. In some embodiments, the marker is a cytokine, such as IL-6, IL-8, VEGF. In some embodiments, the marker is a mucin protein, such as mucin 1, mucin 16, mucin 5B, or mucin 5AC. In some embodiments, the marker is selected from the group consisting of IgGFc binding protein, carbonic anhydrase 1, or cystatin-C, ITIH4, LTF, SERPING1, GC, CFH, FFT1, THSD4, ANPEP, COL6A1, PROM1, and PLG. In each case, increased expression of the protein is associated with unsuitable endometrial environment.
[0044] In some embodiments, the marker is a protein selected from the group consisting of SOD1, PRDX6, PLA2G4D, and TET1, and decreased expression of the protein is associated with an unfavorable endometrial environment.
[0045] In some aspects, the marker is arginine, and decreased levels of arginine are associated with an unfavorable endometrial environment.
[0046] In some embodiments, the marker is PLA2G4D, a member of the phospholipase A2 enzyme family. This protein catalyzes the hydrolysis of glycerophospholipids at sn-2 position, releasing free fatty acids and lysophospholipids. PLA2G4D regulates the eicosanoid pathway and affects the downstream synthesis of prostaglandins responsible for Wnt signaling activation. Reduced PLA2G4D expression indicates an unsuitable endometrial environment.
[0047] In some embodiments, the marker is TET1. TET1 regulates many genes that define cell differentiation. In epiblast cells, TET1 demethylates gene promoters by hydroxymethylation and maintains telomere stability. The reduction of TET1 expression is also correlated with the progression of endometrial tumors. The reduction of TET1 expression indicates an unsuitable endometrial environment.
[0048] MicroRNA (miRNA) is a short non-coding regulatory RNA and is an essential component in the regulation of protein expression.MicroRNA contributes to the crosstalk between endometrium and embryo, and is essential for successful implantation.In some embodiments, the marker is microRNA, for example, hsa-miR-891a, hsa-miR-522, hsa-miR-198, or hsa-miR-365.The reduction in the presence of microRNA is associated with unsuitable endometrial environment. In other embodiments, the microRNA is hsa-miR-135a, hsa-miR-17, hsa-miR-10b, hsa-miR-126, hsa-miR-155, hsa-miR-19a, hsa-miR-150, hsa-miR-200c, hsa-miR-224, hsa-miR-140, hsa-miR-222, hsa-miR-31, hsa-miR-454, or hsa-miR-106c. Increased presence of the marker is associated with an unfavorable endometrial environment.
[0049] The miR-17 / 92 cluster collectively targets thousands of genes and is involved in numerous cellular processes in both adult organisms and developing embryos. The target genes of the has-miR-17-5p gene are involved in many cellular processes, including cell proliferation, cell differentiation, apoptosis, and cell homeostasis. miR-17 inhibits VEGFA, causing a decrease in cell proliferation, migration, and adhesion. Recombinant VEGF-A significantly increases endometrial epithelial cell adhesion. VEGF-A protein acts specifically on endothelial cells and has various effects, including mediating vascular permeability, angiogenesis, cell proliferation, cell migration, and inhibiting apoptosis. In some aspects, a greater than two-fold increase in miR-17 is associated with an unsuitable endometrial environment.
[0050] In some embodiments, the marker is an amino acid, such as arginine. Arginine is necessary for the survival, growth, and development of the conceptus during the peri-implantation period. In the embryo, arginine is important for cell proliferation. Changes in arginine expression, which are involved in excessive inflammatory response and vascular dysfunction, are associated with reduced endometrial implantation capacity and recurrent spontaneous abortion. Reduced arginine in the uterine environment may affect implantation due to lack of motility. Changes in arginine expression may also be involved in the mechanism of excessive inflammatory response and vascular dysfunction, which are associated with reduced endometrial implantation capacity in women who experience recurrent spontaneous abortion (Banerjee et al. 2014).
[0051] Interestingly, a reduction in arginine in the uterine environment may further affect implantation, not due to a lack of adhesion but rather a lack of motility (Gonzalez et al. 2012), preventing the blastocyst from implanting at the appropriate implantation site.
[0052] In some embodiments, the marker is a metabolite, such as urate, xanthine, docosahexaenoic acid, fumarate, cysteine, citrate, putrescine, proline, orthophosphate, leucine / isoleucine, hypoxanthine, heptanoic acid, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline.The decreased presence of the marker is associated with an unsuitable endometrial environment.
[0053] According to the methods, systems, and kits provided herein, the markers can be used alone or in combination. For example, the methods, systems, or kits can be used to detect IL-6, IL-8, VEGF, mucin 1, mucin 16, mucin 5B, mucin 5AC, IgGFc binding protein, carbonic anhydrase 1, cystatin-C, hsa-miR-891a, hsa-miR-522, hsa-miR-198, hsa-miR-365, hsa-miR-135a, hsa-miR-17, hsa-miR-10b, hsa-miR-126, hsa-miR-155, hsa-miR-19a, hsa-miR-150, hsa-miR-200c, hsa-miR-224, hsa-miR-140, hsa-miR-200c, hsa-miR-224, hsa-miR-200c, hsa-miR-224, hsa-miR-200c, hsa-miR-224, hsa-miR-200c, hsa-miR-224, hsa-miR-200c, hsa-miR-224, hsa-miR-220c ... It is contemplated herein that any one or more of miR-222, hsa-miR-31, hsa-miR-454, or hsa-miR-106c, arginine, urate, xanthine, docosahexaenoic acid, fumarate, cysteine, citrate, putrescine, proline, orthophosphate, leucine / isoleucine, hypoxanthine, heptanoic acid, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline may be utilized in generating a uterine secretome profile.
[0054] In some embodiments, a kit is provided that includes a solid substrate functionalized to identify one or more or at least two markers associated with an unfavorable endometrial environment. The markers can be selected from the group consisting of proteins, metabolites, and miRNAs. In some aspects, the kit includes an immunosorbent assay, a qPCR assay, instructions on how to perform the assay, a model for classifying data obtained from the assay, and / or a secretome profile of endometrial secretions associated with successful pregnancy outcomes.
[0055] In some embodiments, a system for improving the pregnancy success rate of fertility treatment is provided. In some aspects, the system includes predicting a poor pregnancy outcome of a patient undergoing fertility treatment prior to frozen embryo transfer or intrauterine insemination. The predicting step can include determining a secretome profile of the patient's endometrial secretions to identify an increased or decreased presence of markers associated with an unsuitable endometrial environment. Compared to the secretome profile of endometrial secretions of successful pregnancy outcomes, an increased or decreased presence of one or more markers associated with an unsuitable endometrial environment is predictive of a poor pregnancy outcome of the patient.
[0056] In some embodiments, the step of determining the secretome profile of the endometrial secretion comprises contacting the patient's endometrial secretion with a kit comprising a solid substrate functionalized to identify at least two markers associated with an unfavorable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs, and determining the secretome profile of the endometrial secretion to confirm an increase or decrease in the presence of the markers associated with an unfavorable endometrial environment.
[0057] The secretome profile can be generated by data obtained from any method known to those skilled in the art for identifying proteins, metabolites, or microRNAs. For example, data can be obtained by mass spectrometry, immunosorbent assay (e.g., enzyme-linked immunosorbent assay (ELISA)), or qPCR.
[0058] Also provided herein is an in vitro method of screening an infertile patient prior to frozen embryo transfer or intrauterine insemination. In some embodiments, the method includes contacting the patient's endometrial secretion with a kit comprising a solid substrate functionalized to identify one or more or at least two markers associated with an unsuitable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs. The method further includes determining the secretome profile of the endometrial secretion to identify an increased or decreased presence of the markers associated with an unsuitable endometrial environment. Compared to the secretome profile of endometrial secretion of successful pregnancy outcomes, an increased or decreased presence of one or more markers associated with an unsuitable endometrial environment predicts poor pregnancy outcome for the infertile patient. Prediction of poor pregnancy outcome can encourage caregivers to forgo the frozen embryo transfer procedure or intrauterine insemination. Measures can be taken to reduce the unsuitable endometrial environment, including treatments that address the marker(s) associated with the unsuitable endometrial environment for that particular patient. For example, if the VEGF protein expression in the patient's endometrial secretions is decreased compared to a VEGF expression profile indicative of a successful pregnancy outcome, the patient may be treated with recombinant VEGF-A. Similarly, if the miR-17 levels in the patient's endometrial secretions are increased compared to miR-17 levels indicative of a successful pregnancy outcome, the patient may be treated with recombinant VEGF-A.
[0059] Provided herein is a method for treating female infertility.In some embodiments, the method includes: (a) determining the miR-17 level in the endometrial secretion of a patient; (b) treating the patient with increased miR-17 level in the endometrial secretion compared with the miR-17 profile that indicates successful pregnancy outcome with recombinant human VEGF-A; and (c) performing frozen embryo transfer or intrauterine insemination.In some embodiments, step (a) is performed at least 24 hours before step (c).
[0060] A method for predicting implantation failure of a candidate embryo is provided herein.In some embodiments, the method comprises contacting the endometrial secretion of a patient with a kit comprising a solid substrate functionalized to identify one or more or at least two markers associated with an unsuitable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs.The method further comprises determining the secretome profile of the endometrial secretion to confirm the increase or decrease in the presence of the markers associated with an unsuitable endometrial environment.The increase or decrease in the presence of one or more markers associated with an unsuitable endometrial environment compared to the secretome profile of the endometrial secretion of a successful pregnancy outcome predicts implantation failure of the embryo. EXAMPLES
[0061] Example 1: Maternal endometrial secretions 24 hours prior to frozen embryo transfer predict implantation outcome Objective: Successful implantation may depend on a complex dialogue between a competent embryo and a receptive endometrium. On the maternal side, specific biological changes must occur for blastocyst attachment, whereas tight control of signaling pathways is critical for the invading embryo. The aim of this study was to investigate the uterine fluid environment associated with implantation outcome 24 hours before and during euploid embryo transfer.
[0062] Materials and Methods: Infertile patients (n=48) were recruited with IRB consent prior to estradiol / progesterone-supplemented frozen embryo transfer (FET) with euploid blastocysts. Uterine secretions were collected by gentle aspiration (approximately 2-5ul) either 24 hours prior to FET or at the time of FET. Briefly, using a mock transfer protocol typically performed prior to embryo transfer, the tip of an empty embryo transfer catheter, covered with a protective sheath to avoid cervical mucus contamination, was positioned close to the site that would result in embryo implantation. After pulling slightly away from the site so as not to disturb the potential implantation site, a small amount of uterine mucus was aspirated into a 10mL Luer-lock syringe (approximately 5-10ul of uterine mucus). The catheter was then removed, still taking care to avoid cervical mucus contamination. The tip of the catheter containing the aspirate was inserted into a 2mL dolphin-nose microtube and, using sterile scissors, the tip was cut off into the tube and flash frozen in liquid nitrogen. Samples were stored at -80°C until further analysis.
[0063] Uterine secretome analysis was performed blinded to implantation outcomes using qPCR for miRNA analysis (n=12) and mass spectrometry (n=36) for metabolite (UHPLS-MS, Thermo) and protein (LC-MS / MS, Thermo) analysis. miRNA profiles were analyzed by REST© statistical software. MS data were transformed with MassMatrix and processed with Maven (Princeton Univ). MS / MS data were interrogated using Mascot™ (v2.2) and Scaffold (v2.06). Target gene validation was performed using qPCR on endometrial biopsies (n=14) and excess cryopreserved blastocysts (n=14) provided with patient consent.
[0064] Results: A prominent uterine secretome profile of miRNAs, metabolites, and proteins was significantly associated with a poor and toxic environment both 24 hours before and at the time of embryo transfer ( P < 0.05, >2-fold change).
[0065] Specifically, several maternal miRNAs showed decreased expression in poor implantation, and several miRNAs, including miR-17, showed increased expression in poor implantation (P<0.05). See Tables 1 and 2. A known target gene of miR-17 through negative regulation is VEGFA, a signal protein essential for implantation that is secreted not only by the implanted embryo but also by the receiving endometrium. Validation of VEGFA expression was confirmed in epithelial endometrial cells and individual blastocysts. [Table 1] [Table 2]
[0066] A total of 17 metabolites showed significant reductions (P<0.05, >2-fold change) in the uterine secretome associated with poor implantation, including arginine, which is essential for blastocyst activation and trophectoderm motility, as well as urate, xanthine, docosahexaenoic acid, fumarate, cysteine, citrate, putrescine, proline, orthophosphate, leucine / isoleucine, hypoxanthine, heptanoic acid, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline (see Figures 1-5).
[0067] Of the 30 cytokines tested, 3 cytokines were associated with poor implantation: VEGF, IL-6 and IL-8. See Figure 6. Cytokines were identified by ELISA.
[0068] A total of 469 proteins were screened by LC-MS / MS. Seven proteins had increased expression associated with poor pregnancy outcome (P<0.05): mucin 1, mucin 16, mucin 5B, mucin 5AC, IgGFc binding protein, carbonic anhydrase 1, and cysteine-C. Mucins are glycosylated epithelial cell surface proteins that have substantial effects on endometrial function, creating a barrier for implantation. Overexpression of mucin proteins was associated with the maintenance of a nonacceptive uterine surface.
[0069] Conclusions: Abnormal maternal uterine miRNA and molecular secretions allow the characterization of implantation failure both 24 h before and at the time of FET. This impaired embryo-endometrial dialogue further affects the transcriptional levels of key signaling molecules, resulting in a significant reduction in implantation success. Predicting the maternal molecular microenvironment prior to embryo transfer allows fine-tuning the patient procedure, thereby improving implantation outcomes.
[0070] Example 2: Minimally invasive uterine aspiration 24 hours prior to embryo transfer characterizes the compromised RIF uterine microenvironment and predicts reproductive outcomes Objective: Recurrent implantation failure (RIF) is particularly challenging to treat, with limited success even when adequate endometrial preparation is established and transfer is performed with high-grade euploid blastocysts. The aim of this study was to utilize a multidisciplinary approach to decipher the complexity of RIF through the investigation of maternal molecular components prior to embryo transfer.
[0071] Materials and Methods: Patients were recruited with IRB consent 24 hours before scheduled frozen embryo transfer (FET) with euploid blastocysts. Uterine secretions were collected (approximately 2-5 μl) by gentle aspiration under ultrasound guidance and grouped according to reproductive outcome: failed euploid FET (RIF patients, ≥3 previous IVF failures) and successful live birth FET (patients matched for maternal age, mean 36.6 ± 3.8 years). Total and small RNA (n = 22) were isolated for sequencing on a NovaSEQ 6000 (Illumina). Reads were aligned to hg38 using GSNAP and analyzed using edgeR (FDR cutoff 5%, P < 0.01). Metabolite analysis (n = 20) was performed by UHPLS-MS (Thermo) using MassMatrix and Maven (Princeton Univ.). Proteomic analysis (n=6) included FASP digestion and LC-MS / MS, and protein identification was generated by Mascot (v2.6) and Scaffold (v4.8.9) (α of 0.05, fold change >1.5 or <0.5).
[0072] Results: A unique uterine microenvironment was observed 24 hours prior to embryo transfer for RIF patients and poor implantation outcomes (P<0.05). Focusing on 13 significantly decreased transcripts, 7 significantly increased maternal miRNAs, 12 significantly decreased amino acids, and 16 significantly altered abundance proteins, the interplay of several biological processes was evident in failed RIF aspirates (P<0.05). See Tables 3 and 4. Specific examples include decreased expression of PLA2G4D (P<0.0001), which regulates the ecosanoid pathway and thereby influences downstream synthesis of prostaglandins such as PGE2; decreased expression of TET1, an epigenetic regulator required for DNA methylation (P<0.0001); increased expression of miR-17, a known negative regulator of VEGFA required for successful implantation (P<0.01); decreased amounts of arginine, which is essential for blastocyst activation and trophectoderm motility (P<0.05); and increased abundance of SERPING1, an inflammation-associated protein that regulates complement activation (P<0.05). [Table 3] [Table 4]
[0073] Conclusions: Analysis of uterine secretions 24 h before FET allows detailed molecular characterization of the impaired RIF uterine microenvironment and predicts reproductive outcome. We identified alterations in amino acid and protein concentrations, as well as negative effects on key miRNA and gene transcription levels, all as important contributors to poor RIF outcome. These findings will facilitate more effective clinical interventions in this challenging patent population. The present invention provides, for example, the following items. (Item 1) 1. A method for predicting poor pregnancy outcome of an infertility treatment, comprising: contacting the patient's endometrial secretion with a kit comprising a solid substrate functionalized to identify one or more or at least two markers associated with an unfavorable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs; determining a secretome profile of said endometrial secretions to identify an increased or decreased presence of markers associated with an unfavorable endometrial environment; A method, wherein said increase or decrease in the presence of said one or more markers associated with an unfavourable endometrial environment compared to a secretome profile of endometrial secretions of successful pregnancy outcomes is predictive of poor pregnancy outcome. (Item 2) 2. The method of claim 1, wherein the marker is a protein selected from the group consisting of IL-6, IL-8, VEGF, mucin 1, mucin 16, mucin 5B, mucin 5AC, IgGFc binding protein, carbonic anhydrase 1, cystatin C, ITIH4, LTF, SERPING1, GC, CFH, FFT1, THSD4, ANPEP, COL6A1, PROM1, and PLG, and increased expression of the protein is associated with an unfavorable endometrial environment. (Item 3) 2. The method of claim 1, wherein the marker is a protein selected from the group consisting of SOD1, PRDX6, PLA2G4D, and TET1, and a decrease in expression of the protein is associated with an unfavorable endometrial environment. (Item 4) 2. The method of claim 1, wherein the marker is arginine and a decrease in the level of arginine is associated with an unfavorable endometrial environment. (Item 5) Item 6. The method of item 1, wherein the marker is a microRNA selected from the group consisting of hsa-miR-891a, hsa-miR-522, hsa-miR-198, and hsa-miR-365, the decreased presence of which is associated with an unfavorable endometrial environment. 2. The method of claim 1, wherein the marker is a microRNA selected from the group consisting of hsa-miR-135a, hsa-miR-17, hsa-miR-10b, hsa-miR-126, hsa-miR-155, hsa-miR-19a, hsa-miR-150, hsa-miR-200c, hsa-miR-224, hsa-miR-140, hsa-miR-222, hsa-miR-31, hsa-miR-454, hsa-miR-106c, the increased presence of which is associated with an unfavorable endometrial environment. (Item 7) 2. The method of claim 1, wherein the marker is a metabolite selected from the group consisting of urate, xanthine, docosahexaenoic acid, fumarate, cysteine, citrate, putrescine, proline, orthophosphate, leucine / isoleucine, hypoxanthine, heptanoic acid, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline, whose decreased presence is associated with an unfavorable endometrial environment. (Item 8) A kit comprising a solid substrate functionalized to identify one or more or at least two markers associated with an unfavorable endometrial environment selected from the group consisting of proteins, metabolites, and miRNAs. (Item 9) 9. The kit of item 8, wherein the marker is a protein selected from the group consisting of IL-6, IL-8, VEGF, mucin 1, mucin 16, mucin 5B, mucin 5AC, IgGFc binding protein, carbonic anhydrase 1, cystatin C, ITIH4, LTF, SERPING1, GC, CFH, FFT1, THSD4, ANPEP, COL6A1, PROM1, and PLG, and increased expression of the protein is associated with an unfavorable endometrial environment. (Item 10) 9. The kit of claim 8, wherein the marker is a protein selected from the group consisting of SOD1, PRDX6, PLA2G4D, and TET1, and a decrease in expression of the protein is associated with an unfavorable endometrial environment. (Item 11) 9. The kit of item 8, wherein the marker is arginine and a decrease in arginine levels is associated with an unfavorable endometrial environment. (Item 12) 9. The kit of item 8, wherein the marker is a microRNA selected from the group consisting of hsa-miR-891a, hsa-miR-522, hsa-miR-198, and hsa-miR-365, the decreased presence of which is associated with an unfavorable endometrial environment. (Item 13) 9. The kit of item 8, wherein the marker is a microRNA selected from the group consisting of hsa-miR-135a, hsa-miR-17, hsa-miR-10b, hsa-miR-126, hsa-miR-155, hsa-miR-19a, hsa-miR-150, hsa-miR-200c, hsa-miR-224, hsa-miR-140, hsa-miR-222, hsa-miR-31, hsa-miR-454, hsa-miR-106c, whose increased presence is associated with an unfavorable endometrial environment. (Item 14) 9. The kit of item 8, wherein the marker is a metabolite selected from the group consisting of urate, xanthine, docosahexaenoic acid, fumarate, cysteine, citrate, putrescine, proline, orthophosphate, leucine / isoleucine, hypoxanthine, heptanoic acid, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline, whose decreased presence is associated with an unfavorable endometrial environment. (Item 15) 1. A system for improving the pregnancy success rate of infertility treatments, comprising predicting poor pregnancy outcome in a patient undergoing infertility treatment prior to frozen embryo transfer or intrauterine insemination, said predicting comprising determining a secretome profile of the patient's endometrial secretions to identify an increased or decreased presence of markers associated with an unfavourable endometrial environment, The system, wherein said increase or decrease in the presence of one or more markers associated with an unfavorable endometrial environment, as compared to a secretome profile of endometrial secretions of successful pregnancy outcomes, predicts poor pregnancy outcome for said patient. (Item 16) 16. The system of claim 15, wherein the step of determining the secretome profile of endometrial secretions comprises contacting the patient's endometrial secretions with a kit comprising a solid substrate functionalized to identify one or more or at least two markers associated with an unfavorable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs, and determining the secretome profile of the endometrial secretions to confirm an increase or decrease in the presence of markers associated with an unfavorable endometrial environment. (Item 17) 16. The system of claim 15, wherein the marker is a protein selected from the group consisting of IL-6, IL-8, VEGF, mucin 1, mucin 16, mucin 5B, mucin 5AC, IgGFc binding protein, carbonic anhydrase 1, cystatin C, ITIH4, LTF, SERPING1, GC, CFH, FFT1, THSD4, ANPEP, COL6A1, PROM1, and PLG, and increased expression of the protein is associated with an unfavorable endometrial environment. (Item 18) 16. The system of item 15, wherein the marker is a protein selected from the group consisting of SOD1, PRDX6, PLA2G4D, and TET1, and a decrease in expression of the protein is associated with an unfavorable endometrial environment. (Item 19) Item 16. The system of item 15, wherein the marker is arginine and a decrease in arginine levels is associated with an unfavorable endometrial environment. (Item 20) 16. The system of claim 15, wherein the marker is a microRNA selected from the group consisting of hsa-miR-891a, hsa-miR-522, hsa-miR-198, and hsa-miR-365, and a decrease in the presence of the microRNA is associated with an unfavorable endometrial environment. (Item 21) 16. The system of claim 15, wherein the marker is a microRNA selected from the group consisting of hsa-miR-135a, hsa-miR-17, hsa-miR-10b, hsa-miR-126, hsa-miR-155, hsa-miR-19a, hsa-miR-150, hsa-miR-200c, hsa-miR-224, hsa-miR-140, hsa-miR-222, hsa-miR-31, hsa-miR-454, hsa-miR-106c, and increased presence of the microRNA is associated with an unfavorable endometrial environment. (Item 22) 16. The system of claim 15, wherein the marker is a metabolite selected from the group consisting of urate, xanthine, docosahexaenoic acid, fumarate, cysteine, citrate, putrescine, proline, orthophosphate, leucine / isoleucine, hypoxanthine, heptanoic acid, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline, and a decreased presence of the metabolite is associated with an unfavorable endometrial environment. (Item 23) Item 16. The system of item 15, wherein the secretome profile is obtained by mass spectrometry. (Item 24) Item 16. The system of item 15, wherein the secretome profile is obtained by data generated by enzyme-linked immunosorbent assay (ELISA). (Item 25) Item 16. The system of item 15, wherein the secretome profile is obtained by qPCR. (Item 26) An in vitro method of screening an infertile patient for frozen embryo transfer or intrauterine insemination, comprising contacting an endometrial secretion of the patient with a kit comprising a solid substrate functionalized to identify one or more or at least two markers associated with an unfavorable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs; determining a secretome profile of said endometrial secretions to identify an increased or decreased presence of markers associated with an unfavorable endometrial environment; A method wherein said increase or decrease in the presence of one or more markers associated with an unfavourable endometrial environment, as compared to a secretome profile of endometrial secretions of successful pregnancy outcomes, predicts poor pregnancy outcome. (Item 27) 27. The method of claim 26, wherein the marker is a protein selected from the group consisting of IL-6, IL-8, VEGF, mucin 1, mucin 16, mucin 5B, mucin 5AC, IgGFc binding protein, carbonic anhydrase 1, cystatin C, ITIH4, LTF, SERPING1, GC, CFH, FFT1, THSD4, ANPEP, COL6A1, PROM1, and PLG, and increased expression of the protein is associated with an unfavorable endometrial environment. (Item 28) 27. The method of claim 26, wherein the marker is a protein selected from the group consisting of SOD1, PRDX6, PLA2G4D, and TET1, and a decrease in expression of the protein is associated with an unfavorable endometrial environment. (Item 29) 27. The method of claim 26, wherein the marker is arginine and a decrease in the level of arginine is associated with an unfavorable endometrial environment. (Item 30) 27. The method of claim 26, wherein the marker is a microRNA selected from the group consisting of hsa-miR-891a, hsa-miR-522, hsa-hsa-miR-198, and hsa-miR-365, the decreased presence of which is associated with an unfavorable endometrial environment. (Item 31) 27. The method of claim 26, wherein the marker is a microRNA selected from the group consisting of hsa-miR-135a, hsa-miR-17, hsa-miR-10b, hsa-miR-126, hsa-miR-155, hsa-miR-19a, hsa-miR-150, hsa-miR-200c, hsa-miR-224, hsa-miR-140, hsa-miR-222, hsa-miR-31, hsa-miR-454, hsa-miR-106c, whose increased presence is associated with an unfavorable endometrial environment. (Item 32) 27. The method of claim 26, wherein the marker is a metabolite selected from the group consisting of urate, xanthine, docosahexaenoic acid, fumarate, cysteine, citrate, putrescine, proline, orthophosphate, leucine / isoleucine, hypoxanthine, heptanoic acid, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline, whose decreased presence is associated with an unfavorable endometrial environment. (Item 33) 1. A method for predicting implantation failure of a candidate embryo, comprising: contacting the patient's endometrial secretion with a kit comprising a solid substrate functionalized to identify one or more or at least two markers associated with an unfavorable endometrial environment selected from the group consisting of proteins, metabolites, or miRNAs; determining a secretome profile of said endometrial secretions to ascertain an increase or decrease in the presence of markers associated with an unfavorable endometrial environment; A method wherein said increase or decrease in the presence of one or more markers associated with an unfavourable endometrial environment, as compared to a secretome profile of endometrial secretions of a successful pregnancy outcome, is predictive of embryo implantation failure. (Item 34) 34. The method of claim 33, wherein the marker is a protein selected from the group consisting of IL-6, IL-8, VEGF, mucin 1, mucin 16, mucin 5B, mucin 5AC, IgGFc binding protein, carbonic anhydrase 1, cystatin C, ITIH4, LTF, SERPING1, GC, CFH, FFT1, THSD4, ANPEP, COL6A1, PROM1, and PLG, and increased expression of the protein is associated with an unfavorable endometrial environment. (Item 35) 34. The method of claim 33, wherein the marker is a protein selected from the group consisting of SOD1, PRDX6, PLA2G4D, and TET1, and a decrease in expression of the protein is associated with an unfavorable endometrial environment. (Item 36) 34. The method of claim 33, wherein the marker is arginine and a decrease in the level of arginine is associated with an unfavorable endometrial environment. (Item 37) 34. The method of claim 33, wherein the marker is a microRNA selected from the group consisting of hsa-miR-891a, hsa-miR-522, hsa-miR-198, and hsa-miR-365, the decreased presence of which is associated with an unfavorable endometrial environment. (Item 38) 34. The method of claim 33, wherein the marker is a microRNA selected from the group consisting of hsa-miR-135a, hsa-miR-17, hsa-miR-10b, hsa-miR-126, hsa-miR-155, hsa-miR-19a, hsa-miR-150, hsa-miR-200c, hsa-miR-224, hsa-miR-140, hsa-miR-222, hsa-miR-31, hsa-miR-454, hsa-miR-106c, whose increased presence is associated with an unfavorable endometrial environment. (Item 39) 34. The method of claim 33, wherein the marker is a metabolite selected from the group consisting of urate, xanthine, docosahexaenoic acid, fumarate, cysteine, citrate, putrescine, proline, orthophosphate, leucine / isoleucine, hypoxanthine, heptanoic acid, alanine, adenosine, 8z-11z-14z-icosatrienoic acid, 8z-11z-14z-17z-icosapentaenoic acid, and 5-oxoproline, whose decreased presence is associated with an unfavorable endometrial environment. (Item 40) 1. A method of treating female infertility, comprising: (a) determining the level of miR-17 in the endometrial secretions of the patient; (b) treating said patients having increased levels of miR-17 in their endometrial secretions relative to a miR-17 profile indicative of a successful pregnancy outcome with recombinant human VEGF-A; (c) performing a frozen embryo transfer or intrauterine insemination. (Item 41) 41. The method of claim 40, wherein (a) is performed at least 24 hours before (c).
Claims
[Claim 1] The invention described in this specification.
Citation Information
Cited By
Magnetic storage device
CN121692997A
